Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 318

Results For "IMI"

3829 News Found

Myonex acquires clinical trial and drug wholesale business of Hubertus in Berlin
Biotech | February 28, 2022

Myonex acquires clinical trial and drug wholesale business of Hubertus in Berlin

Clinical trial supply company strengthens its presence in the European Union


Researchers develop a fast, efficient tech to remove pollutants from water
Sustainability | February 28, 2022

Researchers develop a fast, efficient tech to remove pollutants from water

The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes


Oxford BioDynamics launches its Checkpoint Inhibitor response test in the US
Biotech | February 27, 2022

Oxford BioDynamics launches its Checkpoint Inhibitor response test in the US

First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)


Cantex and Harvard's Wyss Institute to expand development of Azeliragon
News | February 27, 2022

Cantex and Harvard's Wyss Institute to expand development of Azeliragon

Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.


8 bulk drugs projects commissioned under PLI scheme
News | February 26, 2022

8 bulk drugs projects commissioned under PLI scheme

The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa


Jardiance approved to treat adults with heart failure regardless of left ventricular ejection fraction
Drug Approval | February 25, 2022

Jardiance approved to treat adults with heart failure regardless of left ventricular ejection fraction

Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction


Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb
Biotech | February 25, 2022

Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb

It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).


Sanofi and GSK to seek regulatory authorization for Covid-19 vaccine
News | February 24, 2022

Sanofi and GSK to seek regulatory authorization for Covid-19 vaccine

100% efficacy against severe Covid-19 disease and hospitalizations


Philips on track with its ESG  commitments
Sustainability | February 24, 2022

Philips on track with its ESG commitments

Circular revenues already at 16% of sales, driven by healthcare informatics and services to enhance medical equipment uptime and utilization, system and software upgrades for enhanced functionality and extended lifetime and reusing refurbished parts and systems


Omicron sublineage BA.2 a Variant of Concern: WHO
News | February 23, 2022

Omicron sublineage BA.2 a Variant of Concern: WHO

As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern